Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Predict response to decitabine in patients with myelodysplastic syndrome and related neoplasms].

Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi - 14 Feb 2017

Zhao Y S, Guo J, Xu F, Wu D, Wu L Y, Song L L, Xiao C, Li X, Chang C K

Abstract excerpt

Objective: To identify clinical and molecular signatures for predicting response to decitabine (DAC) in patients with myelodysplastic syndrome (MDS) and related neoplasms. Methods: The clinical characteristics of 109 patients with MDS and related neoplasms who were treated with DAC were analyzed retrospectively and the next target sequencing was performed to define recurrently mutated genes in these disease...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Azacitidine
Share to Chromosome Aberrations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chromosomes, Human, Pair 7

Share to Decitabine

Share to Karyotype

Share to Myelodysplastic Syndromes

Share to Neoplasms

Share to Remission Induction

Source

Open in PubMed Open full text

Identifiers

PMID: 28279036
DOI: 10.3760/cma.j.issn.0253-2727.2017.02.008
PMCID: PMC7354175

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Predict response to decitabine in patients with myelodysplastic syndrome and related neoplasms].PMID 28279036Read ↗

TP53 mutations predict decitabine-induced complete responses in patients with myelodysplastic syndromes.Semantic proximity Read ↗

[The Epigenetic Regulation of Decitabine Resistance in TP53 -Mutated Myelodysplastic Syndromes: Integrated Analysis Based on RNA-seq and Methylomics].Semantic proximity Read ↗

TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes.Semantic proximity Read ↗

[Molecular international prognostic scoring system for myelodysplastic syndromes].Semantic proximity Read ↗

[Characteristics and Clinical Significance of Gene Mutation in Patients with Myelodysplastic Syndrome].Semantic proximity Read ↗

Clinical outcomes and characteristics of patients with TP53-mutated myelodysplastic syndromes.Semantic proximity Read ↗

TP53 mutations are associated with very complex karyotype and suggest poor prognosis in newly diagnosed myelodysplastic syndrome patients with monosomal karyotype.Semantic proximity Read ↗

Integrative Multi-Omics Analysis Unveils the Molecular Mechanisms by Which TP53 Mutation Influence Early Decitabine Resistance in Myelodysplastic Syndrome.Semantic proximity Read ↗

Clinical Characteristics, Prognosis, and Treatment Strategies of TP53 Mutations in Myelodysplastic Syndromes.Semantic proximity Read ↗

Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation.Semantic proximity Read ↗

[Clinical characteristics and prognosis of myelodysplastic neoplasms with chromosome 1 abnormalities].Semantic proximity Read ↗

[A preliminary study on the outcome of lower-risk myelodysplastic syndrome by low-dose decitabine].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.